Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EA-2353 in Retinitis Pigmentosa
NCT05392751Phase 2Terminated
- Sponsor
- Endogena Therapeutics
- Start
- Jun 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of EA-2353 in retinitis pigmentosa (RP) (4 cohorts), sponsored by Endogena Therapeutics. Primary endpoints: Incidence and severity of adverse events at 24 months, Incidence and severity of dose limiting toxicities at 24 months and 1 more. Started Jun 2022; status: terminated.
02
Drugs
EA-2353
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT05392751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05392751.